Antiangiogenic agents targeting different angiogenic pathways have opposite effects on tumor hypoxia in R-18 human melanoma xenografts

by Jon-Vidar Gaustad, Trude G. Simonsen, Lise Mari K. Andersen, Einar K. Rofstad
Published 2017-06-01

Efficacy of a Selective Binder of α_Vβ₃ Integrin Linked to the Tyrosine Kinase Inhibitor Sunitinib in Ovarian Carcinoma Preclinical Models

by Andrea Sartori, Cristina Corno, Michelandrea De Cesare, Eugenio Scanziani, Lucia Minoli, Lucia Battistini, Franca Zanardi, Paola Perego
Published 2019-04-01

Subcellular localization of several structurally different tyrosine kinase inhibitors

by Richard Honeywell, Sarina Hitzerd, Ietje Kathmann, Godefridus Peters
Published 2018-09-01

Prognostic relevance of sunitinib toxicities and comparison of continuous vs. intermittent sunitinib dosing schedule in metastatic renal cell cancer patients

by Çetin Ordu, Kezban N. Pilanci, Nilüfer Avcı, İbrahim Yıldız, Gül Alço, Özkan Demirhan, Ülkühan I. Köksal, Filiz Elbüken, Coskun Tecimer, Gökhan Demir
Published 2016-06-01

A case of successful conversion from everolimus to surgical resection of a giant pancreatic neuroendocrine tumor

by Asahi Sato, Toshihiko Masui, Nao Sankoda, Kenzo Nakano, Yuichiro Uchida, Takayuki Anazawa, Kyoichi Takaori, Yoshiya Kawaguchi, Shinji Uemoto
Published 2017-07-01

Mechanism of Myeloid-Derived Suppressor Cell Accumulation in Cancer and Susceptibility to Reversal by Sunitinib

by Ko, Jennifer S.
Published 2009

Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib

by Fiala O, Ostašov P, Rozsypalová A, Hora M, Šorejs O, Šustr J, Bendová B, Trávníček I, Filipovský J, Fínek J, Büchler T
Published 2021-05-01

Optimization of sequential targeted therapy

by B. Ya. Alekseev, A. S. Kalpinskiy, K. M. Nyushko, I. A. Taraki, A. D. Kaprin
Published 2016-09-01

Individual approach in choosing second-line targeted therapy for metastatic renal cell carcinoma

by B. Ya. Alekseev, I. M. Shevchuk, A. D. Kaprin
Published 2018-07-01

New Target for Precision Medicine Treatment of Giant-Cell Tumor of Bone: Sunitinib Is Effective in the Treatment of Neoplastic Stromal Cells with Activated PDGFRβ Signaling

by Michal Mahdal, Jakub Neradil, Peter Mudry, Silvia Paukovcekova, Iva Staniczkova Zambo, Jiri Urban, Peter Macsek, Lukas Pazourek, Tomas Tomas, Renata Veselska
Published 2021-07-01

Y-box binding protein-1 is crucial in acquired drug resistance development in metastatic clear-cell renal cell carcinoma

by Ninadh M. D’Costa, Matthew R. Lowerison, Peter A. Raven, Zheng Tan, Morgan E. Roberts, Raunak Shrestha, Matthew W. Urban, Cesar U. Monjaras-Avila, Htoo Zarni Oo, Antonio Hurtado-Coll, Claudia Chavez-Munoz, Alan I. So
Published 2020-02-01

Hand-foot skin reaction with sunitinib: A rare case report with review of literature

by Suchibrata Das, Alok K Roy, Srutee Barman, Aritra Roy
Published 2020-01-01

Exploring Biological Predictive Factors of Progression After Surgery in High-Risk Renal Cell Carcinoma: Results From the French Cohort of the Randomized S-TRAC Trial Patients

by Idir Ouzaid, Idir Ouzaid, Solène Florence Kammerer-Jacquet, Zineddine Khene, Alain Ravaud, Jean-Jacques Patard, Karim Bensalah, Nathalie Rioux-Leclercq
Published 2020-06-01

A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours

by Yvonne L. E. Ang, Gwo Fuang Ho, Ross A. Soo, Raghav Sundar, Sing Huang Tan, Wei Peng Yong, Samuel G. W. Ow, Joline S. J. Lim, Wan Qin Chong, Phyu Pyar Soe, Bee Choo Tai, Lingzhi Wang, Boon Cher Goh, Soo-Chin Lee
Published 2020-11-01

Encephalic Leukocytoclastic Vasculitis during Treatment with Sunitinib for Renal Cell Carcinoma: A Case Report

by Maria Massucci, Veronica Mollica, Alessandro Rizzo, Laura Ventrella, Ilaria Maggio, Lisa Manuzzi, Lidia Gatto, Giovanni Brandi, Francesco Massari
Published 2021-01-01

Sorafenib as a second-line treatment in metastatic renal cell carcinoma in Mexico: a prospective cohort study

by Ana Elena Martín-Aguilar, Haidé Núñez-López, Juan C. Ramirez-Sandoval
Published 2021-01-01

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study

by Asim Amin, Elizabeth R Plimack, Marc S Ernstoff, Lionel D Lewis, Todd M Bauer, David F McDermott, Michael Carducci, Christian Kollmannsberger, Brian I Rini, Daniel Y C Heng, Jennifer Knox, Martin H Voss, Jennifer Spratlin, Elmer Berghorn, Lingfeng Yang, Hans J Hammers
Published 2018-10-01

Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-Line Sunitinib (QUASAR): Results of a Phase I Trial

by Carlo Buonerba, Carlo Buonerba, Pietro De Placido, Dario Bruzzese, Martina Pagliuca, Paola Ungaro, Davide Bosso, Dario Ribera, Simona Iaccarino, Luca Scafuri, Antonietta Liotti, Valeria Romeo, Michela Izzo, Francesco Perri, Beniamino Casale, Giuseppe Grimaldi, Francesca Vitrone, Arturo Brunetti, Daniela Terracciano, Alfredo Marinelli, Alfredo Marinelli, Sabino De Placido, Giuseppe Di Lorenzo
Published 2018-03-01

miR-221-3p Regulates VEGFR2 Expression in High-Risk Prostate Cancer and Represents an Escape Mechanism from Sunitinib In Vitro

by Markus Krebs, Antonio Giovanni Solimando, Charis Kalogirou, André Marquardt, Torsten Frank, Ioannis Sokolakis, Georgios Hatzichristodoulou, Susanne Kneitz, Ralf Bargou, Hubert Kübler, Bastian Schilling, Martin Spahn, Burkhard Kneitz
Published 2020-03-01

Retrospective review of experience with sarcomatoid renal cell carcinoma: Multimodality treatment remains an unmet goal

by Gowrinath Kondisetty, Pallavi Vijay Borkar, Sandeep Kondisetty, Appu Thomas
Published 2019-01-01